Radionuclide therapy

被引:78
作者
Chatal, JF [1 ]
Hoefnagel, CA
机构
[1] Ctr Rene Gauducheau, Dept Nucl Med, F-44000 Nantes, France
[2] Netherlands Canc Inst, Dept Nucl Med, Amsterdam, Netherlands
关键词
D O I
10.1016/S0140-6736(99)06002-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nuclear medicine therapy uses unsealed radioactive sources for the selective delivery of radiation to tumours or target organs. For benign disorders such as thyrotoxicosis and arthritis radionuclide therapy provides an alternative to surgery or medical treatment. In cancer treatment, it often combines the advantage of target selectivity (like brachytherapy or external beam radiotherapy) with that of being systemic, as with chemotherapy, and it may be used as part of a therapeutic strategy with curative intent or for disease control and palliation. Toxicity is generally limited to the haematopoietic tissue and few side-effects are observed. When cure is feasible, the long-term consequences of radionuclide therapy (eg, fertility disorders and leukaemia or other secondary cancers) do compare favourably with the risks associated with and accepted for chemotherapy and radiotherapy.
引用
收藏
页码:931 / 935
页数:5
相关论文
共 21 条
[1]  
Chatal JF., 1998, NUCL MED CLIN DIAGNO, P1101
[2]   FIRST LINE TARGETED RADIOTHERAPY, A NEW CONCEPT IN THE TREATMENT OF ADVANCED-STAGE NEUROBLASTOMA [J].
DEKRAKER, J ;
HOEFNAGEL, CA ;
CARON, H ;
OLMOS, RAV ;
ZSIROS, J ;
HEIJ, HA ;
VOUTE, PA .
EUROPEAN JOURNAL OF CANCER, 1995, 31A (04) :600-602
[3]  
Hnatowich DJ, 1999, J NUCL MED, V40, P693
[4]   Radionuclide therapy practice and facilities in Europe [J].
Hoefnagel, CA ;
Clarke, SEM ;
Fischer, M ;
Chatal, JF ;
Lewington, VJ ;
Nilsson, S ;
Vieira, MR .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (03) :277-282
[5]  
HUMM JL, 1990, J NUCL MED, V31, P75
[6]  
LUI SY, 1998, J CLIN ONCOL, V16, P3270
[7]  
Maloney DG, 1997, BLOOD, V90, P2188
[8]   Radioimmunotherapy with alpha-emitting nuclides [J].
McDevitt, MR ;
Sgouros, G ;
Finn, RD ;
Humm, JL ;
Jurcic, JG ;
Larson, SM ;
Scheinberg, DA .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (09) :1341-1351
[9]   Yttrium-90-labelled somatostatin-analogue for cancer treatment [J].
Otte, A ;
Mueller-Brand, J ;
Dellas, S ;
Nitzsche, EU ;
Herrmann, R ;
Maecke, HR .
LANCET, 1998, 351 (9100) :417-418
[10]  
Quirijnen JMSP, 1996, J NUCL MED, V37, P1511